AN OPEN-LABEL EXTENSION STUDY OF DS-5565 FOR 52 WEEKS IN PAIN ASSOCIATED WITH FIBROMYALGIA
Phase of Trial: Phase III
Latest Information Update: 14 Aug 2017
At a glance
- Drugs Mirogabalin (Primary)
- Indications Fibromyalgia; Pain
- Focus Adverse reactions
- Sponsors Daiichi Sankyo Inc
- 01 Jul 2017 This trial was completed in Slovenia (end date: 2017-04-19), according to European Clinical Trials Database.
- 30 Jun 2017 Status changed from active, no longer recruiting to completed, according to a Daiichi Sankyo media release.
- 25 Jun 2017 This trial has been completed in Portugal (end date: 2017-04-19) as per European Clinical Trials Database record.